Search results for " Treatment resistance"

showing 2 items of 2 documents

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.

2004

The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis is unclear. In a retrospective multicenter study, we have analyzed the virological events observed during lamivudine therapy in patients with HBeAg-negative chronic hepatitis and evaluated the correlation between virological response and clinical outcomes. Among 656 patients (mean age 49.1 years) included in the database, 54% had chronic hepatitis, 30% had Child-Turcotte-Pugh (CTP) A cirrhosis, and 16% had CTP B/C cirrhosis. On therapy (median 22 months, range 1–66), a virological response was obtained in 616 patients (93.9%). The rate of maintained virological respons…

AdultMalemedicine.medical_specialtyANTIVIRAL TREATMENTHepatitis B virusCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentEpatite cronica da Virus B trattamento antiviraleLAMIVUDINE; ANTIVIRAL TREATMENT; CHRONIC HEPATITIS B; TREATMENT RESISTANCECHRONIC HEPATITIS BLiver transplantationGastroenterologyLiver diseaseHepatitis B ChronicInternal medicineMedicineHumansHepatitis B e AntigensAgedRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsTREATMENT RESISTANCELamivudineHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSurvival RateTreatment OutcomeHBeAgLamivudineHepatocellular carcinomaMultivariate AnalysisMutationReverse Transcriptase InhibitorsFemalebusinessViral loadmedicine.drugHepatology (Baltimore, Md.)
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct